Healthcare · Profile from Healthcare Research Companion
GoodRx Holdings, Inc.
The consumer price-comparison site and discount-card network that made US cash prescription prices visible and turned the hidden economics of pharmacy benefit managers (PBMs) into a consumer brand. It earns most of its money from fees that PBMs pay when a patient fills a prescription using a GoodRx code. Founded in 2011 by tech executives who were annoyed by pharmacy pricing, it was profitable early, went public in 2020 at a valuation of more than $12bn, and then spent five years learning how much of its fate depended on pharmacies and PBMs it did not control: a grocery chain dispute in 2022, an FTC privacy penalty in 2023, founder departures, pharmacy closures, and a pivot toward drug-manufacturer revenue.
At a glance
- Founded
- 2011, Santa Monica, California
- Founders
- Doug Hirsch (ex-Yahoo and Facebook product executive), Trevor Bezdek (co-CEO) and Scott Marlette (technology)
- Headquarters
- Santa Monica, California
- Ownership / structure
- Public company, Nasdaq: GDRX (IPO September 2020); dual-class shares; private-equity holders Silver Lake and Francisco Partners kept large stakes after the IPO (verify current holdings)
- Leadership (2026)
- Wendy Barnes, President and CEO (from January 2024); Chris McGinnis, CFO through 2025 results, with Justin Fengler named incoming CFO in 2026 (verify titles and dates)
- Segment and buyer
- Digital health / pharmacy & PBM adjacency. Consumers use it free; PBMs pay per-fill fees; drug manufacturers pay for marketing and affordability programs; subscribers pay for GoodRx Gold
- Scale
- Millions of monthly consumers (~6m+ monthly active consumers at its 2021–22 peak, reported, verify); 2024 revenue $792.3m; 2025 revenue $796.9m (+~1%); 2026 guidance $765–785m after Q1, raised again after Q2 (Q2 2026 revenue $200.4m, adjusted EBITDA margin ~31.8%) (verify)
- Capital / valuation
- Few outside rounds before 2018 (Francisco Partners and Spectrum Equity growth investment, October 2015, reported as a majority stake); Silver Lake-led investment in 2018 at ~$2.8bn (reported, verify); IPO raised ~$1.1bn at $33/share; first-day market cap ~$18bn+; market cap fell below ~$2–3bn in 2023–26 (verify)
- Signature moves (incl. failures)
- Founding and price comparison (2011); GoodRx Gold (2017); Silver Lake investment (2018); HeyDoctor and GoodRx Care telehealth (2019); IPO (2020); grocery-chain (Kroger) shock (2022); FTC health-data settlement (2023); founder co-CEO exit and restructuring (2023); Integrated Savings and Pharma Direct pivot (2023–26)
9 strategic moves analysed
Each one gets a full strategy file in the companion: context, the decision, the financing, what happened, and the lesson.
2011
Founding and Price Comparison
Founding / launch
2017
GoodRx Gold Subscription
Launch / pricing change
2018
Silver Lake Investment
Funding round (private-equity growth investment, largely secondary)
2019
HeyDoctor and GoodRx Care
Acquisition / launch
2020
IPO
IPO
2022
Kroger Grocery Chain Shock
Partnership failure / guidance cut (a supplier-side shock rather than a planned move)
2023
FTC Health Data Settlement
Regulatory settlement
2023
Founder CEO Transition and Restructuring
Restructuring (leadership change and cost reset)
2023
Integrated Savings and Pharma Direct
Pivot / partnership (from consumer coupons toward embedded pricing and manufacturer revenue)